Podcast Special: The Shifting Landscape For Drugs And Devices Post-Roe v. Wade
A special podcast featuring editors Elizabeth Orr and Marion Webb from Medtech Insight, Brenda Sandburg from Pink Sheet and Malcolm Spicer from HBW Insight discussing the US Supreme Court’s historic overturning of Roe v. Wade and implications for FDA-regulated sectors, from the abortion pill and OTC daily and emergency contraceptives to intrauterine devices and period-tracking apps.
You may also be interested in...
Getting Personal With Brittany Barreto: From One-Time ‘Science Hater’ To Genetics Doctorate, DNA Dating App And Women’s Health Champion
Brittany Barreto, CEO of FemHealth Insights, who participated in a panel discussion at SXSW 2023 on the $1t femtech industry, talks about her journey to becoming a women’s health care champion.
The US FDA has scheduled a joint advisory committee meeting for November to review Perrigo subsidiary HRA Pharma’s new drug application for Rx-to-OTC switch of Opill (0.075-mg norgestrel), which would represent the first birth control pill available in the US without a prescription.
People have challenged patent listings more than 60 times in the past six years but it is up to new drug application holders to decide whether to revise or delist their submissions.